Just caught Relay Therapeutics' earnings and the stock jumped 19% today—hitting a new 52-week high at $10.98. Pretty solid move for a clinical-stage biotech, and there's actually substance behind it.

Looking at the numbers, they managed to narrow their Q4 net loss significantly to $54.9 million versus $76 million a year ago. Full-year 2025 losses came in at $276.5 million, down from $337.7 million in 2024. More importantly, they're actually generating revenue now—$15.4 million for the year, up from $10 million, thanks to their licensing deal with Elevar Therapeutics.

But here's what really matters: their pipeline is starting to show real momentum. Zovegalisib (RLY-2608), their lead candidate, is running a Phase 3 trial for HR+/HER2- metastatic breast cancer and they're expecting triplet combination data this year. They've also got this Phase 1/2 study for PI3Ka-driven vascular anomalies with initial readouts coming soon. Then there's RLY-8161, an NRAS-selective inhibitor still in preclinical work, and a Fabry disease program in early clinical testing. They even out-licensed Lirafugratinib to Elevar, which creates a nice revenue relay where milestone payments flow back to them.

What stands out is the cash position—they ended 2025 with $554.5 million, which should fund operations into 2029. That gives them real runway to see these programs through.

CEO Sanjiv Patel called 2026 a pivotal year, and honestly, with multiple clinical readouts expected across their cancer and vascular programs, this could be a company that actually jumps from clinical-stage to commercialization phase. The stock was trading between $1.77 and $10.98 over the past year, so today's move to the high end shows investors are taking the pipeline progress seriously. Worth keeping on the radar if you follow biotech.